Genetic Testing for Breast Cancer in the Era of Multigene Panels: Can We Make an Impact on Population Health?
Menée au Nigeria auprès de 1 136 patientes atteintes d'un cancer invasif du sein de stade III ou IV (âge moyen : 47,5 ans) et auprès de 997 témoins (âge moyen : 47 ans), cette étude évalue la proportion de cas résultant d'une mutation génétique héréditaire (BRCA1, BRCA2, PALB2, TP53, ...)
Breast cancer is an important public health problem in Nigeria. With an estimated age-standardized rate of approximately 50 per 100,000 per year, it is the most common cancer in women, representing approximately 40% of all cancers and approximately one third of cancer deaths among women. In 2012, this amounted to > 27,000 new cases and 13,000 deaths, reflecting a high case fatality ratio.1 Projections to 2030 indicate that new cases per year will increase by at least 60% because of the demographic transition alone, with potential further increases due to changes in risk factors.
Journal of Clinical Oncology , éditorial en libre accès, 2017